ArticleDrug delivery and translational research2026
Oleyl-hyaluronate nanoparticles for enhanced peroral bioavailability of encapsulated Coenzyme Q10.
Article in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immunological drivers of oxidative stress in glaucoma: implications for antioxidant therapy.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Hyaluronic acid (HA) is a biocompatible, mucosal-interacting polysaccharide that offers unique advantages for oral drug delivery. Chemical modification with hydrophobic groups transforms HA into an amphiphilic polymer capable of self-assembly and encapsulation of poorly soluble compounds. In this work, we developed an oral delivery system based on oleyl-hyaluronate (O-HA) for coenzyme Q10 (CoQ10), a lipophilic antioxidant with limited solubility and low bioavailability. The coenzyme Q10-loaded oleyl-hyaluronate nanoparticles (O-HAQ10) were prepared using a multistep solvent evaporation method, achieving a high CoQ10 loading of up to 13.8 g/L and an encapsulation efficiency typically exceeding 90%. Crucially, this platform achieved an exceptionally high drug loading capacity, substantially minimizing the surfactant burden typically required to stabilize highly lipophilic payloads. The nanoparticles exhibited nanoscale dimensions (200-300 nm), as confirmed by dynamic light scattering (DLS) and scanning electron microscopy (SEM). Comprehensive in vitro evaluation confirmed robust cytocompatibility with the Caco-2 human intestinal epithelial cell line. Furthermore, studies on porcine intestine demonstrated significantly enhanced mucosal accumulation compared to commercial liposomal and oil-based formulations, even following simulated gastric exposure. In vivo pharmacokinetic evaluation in mice confirmed a 72% increase in systemic bioavailability relative to the clinical gold-standard oil-based control. These findings highlight the potential of hydrophobically modified HA as a highly efficient, versatile platform for the peroral delivery of poorly soluble bioactives.
Indexed as
Identifiers
41946825What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.